Abstract
Intracellular delivery of functional macromolecules, such as DNA and RNA, across the cell membrane and into the cytosol, is a critical process in both biology and medicine. Herein, we develop and use microfluidic chips containing post arrays to induce microfluidic vortex shedding, or μVS, for cell membrane poration that permits delivery of mRNA into primary human T lymphocytes. We demonstrate transfection with μVS by delivery of a 996-nucleotide mRNA construct encoding enhanced green fluorescent protein (EGFP) and assessed transfection efficiencies by quantifying levels of EGFP protein expression. We achieved high transfection efficiency (63.6 ± 3.44% EGFP + viable cells) with high cell viability (77.3 ± 0.58%) and recovery (88.7 ± 3.21%) in CD3 + T cells 19 hrs after μVS processing. Importantly, we show that processing cells via μVS does not negatively affect cell growth rates or alter cell states. We also demonstrate processing speeds of greater than 2.0 × 10<sup>6</sup> cells s<sup>-1</sup> at volumes ranging from 0.1 to 1.5 milliliters. Altogether, these results highlight the use of μVS as a rapid and gentle delivery method with promising potential to engineer primary human cells for research and clinical applications.
Introduction
Gene-modified cell therapies (GMCT), such as CAR-T cells, are transforming cancer treatment, but manufacturing them remains a major bottleneck. Currently, researchers rely on two main methods for gene delivery: viral transduction and electroporation. Viral methods are effective but extremely expensive and time-consuming. Electroporation, while versatile, uses high-voltage electricity to create membrane pores, which is often cytotoxic and can alter the functional state of surviving cells.
Existing microfluidic alternatives often rely on "cell squeezing," forcing cells through narrow gaps. While effective, these designs are prone to clogging and limited in throughput. This paper introduces Microfluidic Vortex Shedding (μVS), a novel platform designed to be as fast as physical transfection but as gentle as biological processes, capable of processing millions of cells required for clinical applications without mechanical damage.
Mechanism and Device Design
The μVS platform utilizes a microfluidic chip containing arrays of microscopic posts. Unlike constriction-based methods, the gaps between the posts (20 μm) are significantly larger than the target T cells (~10 μm). When a cell suspension is pumped through these arrays at high Reynolds numbers ($Re_o > 40$), the fluid dynamics change to create stable, high-frequency vortices.
These vortices exert transient hydrodynamic forces on the T cells, creating temporary pores in their membranes. This allows mRNA present in the surrounding fluid to diffuse into the cell before the membrane naturally repairs itself. Because the cells are not physically compressed, the risk of clogging is drastically reduced, enabling much higher processing speeds.
Computational Validation
To confirm the underlying physics of the device, the team employed Computational Fluid Dynamics (CFD). The simulations proved that vortices were indeed forming exactly where cell poration was expected to occur.
The Q-criterion analysis specifically highlighted the regions of intense vortex formation, validating that the hydrodynamic forces generated by the post array are sufficient for membrane disruption without requiring mechanical constriction.
Experimental Results
The study utilized primary human T lymphocytes (CD3+, CD4+, and CD8+ subsets) and a 996-nucleotide mRNA construct encoding Enhanced Green Fluorescent Protein (EGFP). Key performance metrics included:
- High Efficiency & Viability: The researchers achieved a transfection efficiency of 63.6% with a cell viability of 77.3% and a recovery rate of 88.7%.
- Exceptional Throughput: The system processed cells at speeds exceeding 2.0 × 10⁶ cells per second.
- Preservation of Cellular State: μVS-treated cells were indistinguishable from untreated cells in terms of growth rates and activation markers (CD69 and CD25). This "stealthy" delivery is a significant advantage over electroporation, which can trigger stress responses.
- Subset Neutrality: The method transfects CD4+ and CD8+ T cells with equal efficiency, which is vital for maintaining the therapeutic balance required in CAR-T products.
Conclusion and Future Outlook
Microfluidic vortex shedding represents a significant step toward efficient "point-of-care" cell engineering. While the current study focused on EGFP mRNA, the platform's high viability and throughput suggest it could be adapted for larger payloads, such as DNA plasmids or CRISPR-Cas9 complexes. By reducing the time and cost associated with cell manufacturing, μVS offers a promising path to making advanced cell therapies more accessible for clinical use.
Summary updated